Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 3OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 267Neoplasms 177Colorectal Neoplasms 133Stomach Neoplasms 107Uterine Cervical Neoplasms 96Carcinoma, Non-Small-Cell Lung 89Prostatic Neoplasms 83Lung Neoplasms 78Carcinoma, Hepatocellular 73Rectal Neoplasms 64Ovarian Neoplasms 54Esophageal Neoplasms 53Pancreatic Neoplasms 52Colonic Neoplasms 52Recurrence 43Multiple Myeloma 39Neoplasm Metastasis 38Head and Neck Neoplasms 37Endometrial Neoplasms 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Motor Activity 34Melanoma 33Polycystic Ovary Syndrome 32Lymphoma 32Urinary Bladder Neoplasms 31Leukemia, Myeloid, Acute 30Thyroid Neoplasms 29Small Cell Lung Carcinoma 28Nasopharyngeal Carcinoma 25Lymphoma, Non-Hodgkin 25

Interventions

pyrotinib 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × HER2 Positive Metastatic Breast Cancer × Clear all
NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Henan Cancer Hospital

Phase 2 Unknown
46 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡